Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)

Market Cap	42.51B +759.7%
Revenue (ttm)	1.78B +43.9%
Net Income	330.18M +250.5%
EPS	0.81 +243.6%
Shares Out	446.90M
PE Ratio	60.54
Forward PE	57.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,074,500
Average Volume	1,376,625
Open	51.35
Previous Close	49.30
Day's Range	48.62 - 53.05
52-Week Range	11.60 - 70.15
Beta	0.13
RSI	46.55
Earnings Date	Apr 27, 2026

About HKG:2315

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provid...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,443
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2315

Financial Performance

In 2025, HKG:2315's revenue was 1.38 billion, an increase of 40.63% compared to the previous year's 980.45 million. Earnings were 173.20 million, an increase of 416.37%.

Financial numbers in CNY